FBIO Stock Analysis: Buy, Sell, or Hold?
FBIO - Fortress Biotech, Inc.
$2.61
-0.04 (-1.51%)
▼
5d:
-5.43%
30d:
+9.66%
90d:
-15.81%
HOLD
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When FBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: FBIO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: FBIO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$0.60
Based on -37.5% avg growth
INTRINSIC VALUE TODAY
$0.37
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: FBIO is currently trading at $2.61, which is considered slightly high relative to its 30-day fair value range of $2.29 to $2.68. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.2) compared to its historical average (178.1). Remarkably, the market is currently pricing in an annual earnings decline of 69.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, FBIO is in a strong downtrend. Immediate support is located at $2.53, while resistance sits at $2.87.
Market Sentiment: FBIO has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+321.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, FBIO is in a strong downtrend. Immediate support is located at $2.53, while resistance sits at $2.87.
Market Sentiment: FBIO has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+321.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$2.29 -
$2.68
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
80.8%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 321.5% below Wall St target ($11.00)
- CAUTION: Recommendation downgraded due to -5.4% 5-day decline
Trading Range Analysis
30-Day Trading Range
$2.29 -
$2.68
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.35
(13.5%)
Support & Resistance Levels
Support Level
$2.53
Resistance Level
$2.87
Current Trend
Strong Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.17
Wall Street Target
$11.00
(+321.5%)
Revenue Growth (YoY)
6.3%
Profit Margin
10.8%
Valuation Discount vs History
-69.3% cheaper
PE vs Historical
5.2 vs 178.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-69.3%
(market-implied from PE analysis)
1-Year Target
$2.35
(-10%)
2-Year Target
$2.11
(-19%)
3-Year Target
$1.90
(-27%)
3-Yr Target (if PE normalizes)
(PE: 5→178)
$65.57
(+2412%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: -79.0%)
$8.07
(+209%)
Base:
(SPY PE: 5.2, Growth: -79.0%)
$1.90
(-27%)
Bear:
(PE: 4.4, Growth: -79.0%)
$1.62
(-38%)
📈
Valuation based on Current Earnings
Trailing PE: 0.86 | Current EPS (TTM): $3.23
Bull Case
$1.53
(-46%)
Analyst growth -50.0%, PE expands to 1.0
Base Case
$1.39
(-51%)
Market implied -50.0%, PE stable at 0.9
Bear Case
$1.89
(-33%)
Severe decline -20.0%, PE contracts to 0.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.2 to 178.1
Stabilization Target:
$89.94
(+3346.0%)
PE Expansion Potential:
+3346.0%
Share & Embed Analysis
Last updated: June 04, 2026 12:42 AM ET
Data refreshes hourly during market hours. Next update: 1:42 AM
Data refreshes hourly during market hours. Next update: 1:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FBIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$446 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1023 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$82 | 58 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 48 HOLD |
